We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Possible ruxolitinib‐induced acquired epidermodysplasia verruciformis and multiple non‐melanoma skin cancers in a patient with polycythemia vera.
- Authors
Demirel Öğüt, Neslihan; Mızrak, Bülent
- Abstract
The patient was started on topical tazarotene therapy; however, no significant benefit was observed at the 6-month follow-up in EV lesions. Treatment options include topical treatments such as cidofovir, retinoids, glycolic acid lotion and imiquimod, HPV vaccine, photodynamic therapy, and systemic retinoids, apart from changing the immunosuppressive agent that causes EV. Therefore, in the case of NMSC development in patients using ruxolitinib, it is recommended to evaluate the patients on a case-by-case basis, and this condition should not limit the use of ruxolitinib in every case.[4] Our patient continues on ruxolitinib treatment with regular skin examination every 3 months.
- Subjects
SKIN cancer; POLYCYTHEMIA vera; CANCER patients
- Publication
Journal of Cosmetic Dermatology, 2022, Vol 21, Issue 11, p6502
- ISSN
1473-2130
- Publication type
Case Study
- DOI
10.1111/jocd.15253